Table 2 Model Parameters

LDL-P relative risk (per SD)

1.40 (1.12–1.75)

Log normal

Melander et al. JACC 2015 [8]

Fraction of CABG in revascularization

0.2 (±20%)

β

Ohsfeldt et al. J Med Econ 2010 [35]

Fraction of fatal MI among MI

0.125 (±20%)

β

Choudhry et al. JACC 2011 [36]

Fraction of fatal stroke among stroke

0.132 (±20%)

β

Choudhry et al. JACC 2011 [36]

Fraction discontinuing statin therapy^a

0.254 (0–0.444)

β

Pletcher et al. CircCQO 2014 [31]

  MI

0.46 (0.30–0.70)

Log normal

Choudhry et al. JACC 2011 [36], Ridker et al. NEJM 2008 [11]

  Revascularization

0.54 (0.41–0.72)

Log normal

Choudhry et al. JACC 2011 [36], Ridker et al. NEJM 2008 [11]

  Stroke

0.52 (0.34–0.79)

Log normal

Choudhry et al. JACC 2011 [36], Ridker et al. NEJM 2008 [11]

  Coronary Artery Disease

0.75 (0.71–0.78)

Log normal

Pandya et al. JAMA 2015 [21]

  Stroke

0.83 (0.76–0.87)

Log normal

Pandya et al. JAMA 2015 [21]

 Disease free off statins

1

unchanged

Assumption

 Disease free taking statins

0.998 (0.991–1.0)

β

Pandya et al. JAMA 2015 [21]

 Post MI

0.778 (0.575–0.843)

β

Sullivan et al. Med Decis Making 2006 [22]

 Post Stroke

0.768 (0.463–0.816)

β

Sullivan et al. Med Decis Making 2006 [22]

 Post PCI or CABG

0.768 (0.517–0.827)

β

Sullivan et al. Med Decis Making 2006 [22]

 Multiple CVD^b

0.605 (±20%)

β

Calculated from Sullivan et al. Med Decis Making 2006 [22]

 Diabetes

0.800 (0.708–0.844)

β

Sullivan et al. Med Decis Making 2006 [22]

 Mild adverse events (disutility)

0.005 (±20%)

β

Lee et al. Circulation 2010 [32]

 Severe adverse events (disutility)

0.038 (±20%)

β

Lee et al. Circulation 2010 [32]

 LDL-P test

42.29 (±20%)

γ

CMS fee schedule [37]

 Nonfatal MI (1^st year)

69,819 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 Fatal MI

19,373 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 Nonfatal stroke (1^st year)

23,021 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 Fatal stroke

11,951 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 CABG (1^st year)

41,388 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 PCI (1^st year)

38,998 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 Diabetes (diagnosis)

138.18 (±20%)

γ

Choudhry et al. JACC 2011 [36]

 Severe adverse events

7,852 (±20%)

γ

Lee et al. Circulation 2010 [32]

 Mild adverse events

199.32 (±20%)

γ

Lee et al. Circulation 2010 [32]

 Low/Moderate-intensity statin therapy (annual)

48.00 (±20%)

γ

www.healthwarehouse.com [39]

 High-intensity statin therapy (annual)

91.00 (±20%)

www.healthwarehouse.com [39]

 MI (subsequent years, annual)

507.83 (±20%)

γ

Choudhry et al. JACC 2011 [36]

 CABG or PCI (subsequent years, annual)

507.83 (±20%)

γ

Assumed to be equal to MI

 Stroke (subsequent years, annual)

20263.60 (±20%)

γ

Choudhry et al. JACC 2011 [36]

 Multiple CVD state (subsequent years, annual)

9968.34 (±20%)

γ

O’Sullivan et al. Pharmacoeconomics 2011 [38]

 Diabetes (annual)

2660.67 (±20%)

γ

Soni, AHRQ statistical brief #304. 2010 [40]